Terms: = Kidney tumors AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Treatment
2497 results:
1. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
Marvaso G; Jereczek-Fossa BA; Zaffaroni M; Vincini MG; Corrao G; Andratschke N; Balagamwala EH; Bedke J; Blanck O; Capitanio U; Correa RJM; De Meerleer G; Franzese C; Gaeta A; Gandini S; Garibaldi C; Gerszten PC; Gillessen S; Grubb WR; Guckenberger M; Hannan R; Jhaveri PM; Josipovic M; Kerkmeijer LGW; Lehrer EJ; Lindskog M; Louie AV; Nguyen QN; Ost P; Palma DA; Procopio G; Rossi M; Staehler M; Tree AC; Tsang YM; Van As N; Zaorsky NG; Zilli T; Pasquier D; Siva S
Lancet Oncol; 2024 May; 25(5):e193-e204. PubMed ID: 38697165
[TBL] [Abstract] [Full Text] [Related]
2. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.
Uhlig J; Uhlig A; Deshpande H; Ströbel P; Trojan L; Lotz J; Hurwitz M; Hafez O; Humphrey P; Grünwald V; Kim HS
Sci Rep; 2024 May; 14(1):10038. PubMed ID: 38693188
[TBL] [Abstract] [Full Text] [Related]
3. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
[TBL] [Abstract] [Full Text] [Related]
4. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
[TBL] [Abstract] [Full Text] [Related]
5. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
Pei F; Tao Z; Lu Q; Fang T; Peng S
World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
[TBL] [Abstract] [Full Text] [Related]
6. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.
Li H; Huntington S; Gross C; Wang SY
PLoS One; 2024; 19(4):e0300789. PubMed ID: 38625861
[TBL] [Abstract] [Full Text] [Related]
7. Robotic salvage partial nephrectomy following surgical and ablative therapies.
Feng CL; Franco A; Ditonno F; Manfredi C; Chow AK; Autorino R
Int Braz J Urol; 2024; 50(3):373-374. PubMed ID: 38598832
[TBL] [Abstract] [Full Text] [Related]
8. Clinical safety and efficacy of microwave ablation for small renal masses.
Foret A; Haaga CB; Jain S; Baumgartner CO; Escott M; Henderson BR; O'Brien ST; Delacroix SE; Gills JRR; Westerman ME
Int Braz J Urol; 2024; 50(3):277-286. PubMed ID: 38598830
[TBL] [Abstract] [Full Text] [Related]
9. Challenges and technical aspects in the management of muscle invasive bladder cancer as retrograde radical cystectomy with ileal conduit.
Nusrat NB; Rehman AU; Zafar N; Muhammad S; Bajwa SI; Imtiaz S
J Pak Med Assoc; 2024 Mar; 74(3):513-518. PubMed ID: 38591289
[TBL] [Abstract] [Full Text] [Related]
10. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP; Tao Y; Licitra L; Burtness B; Tahara M; Rischin D; Alves G; Lima IPF; Hughes BGM; Pointreau Y; Aksoy S; Laban S; Greil R; Burian M; Hetnał M; Delord JP; Mesía R; Taberna M; Waldron JN; Simon C; Grégoire V; Harrington KJ; Swaby RF; Zhang Y; Gumuscu B; Bidadi B; Siu LL;
Lancet Oncol; 2024 May; 25(5):572-587. PubMed ID: 38561010
[TBL] [Abstract] [Full Text] [Related]
11. Long-term outcome of surgically treated and conservatively managed Rathke cleft cysts.
Schmutzer-Sondergeld M; Weller J; Thorsteinsdottir J; Schichor C; Rachinger W; Thon N; Ueberschaer M
Acta Neurochir (Wien); 2024 Apr; 166(1):159. PubMed ID: 38557782
[TBL] [Abstract] [Full Text] [Related]
12. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
[TBL] [Abstract] [Full Text] [Related]
13. Association Between Acute kidney Injury and the Trendelenburg Position Angle During Robot-assisted Radical Prostatectomy.
Masuda H; Amemiya Y; Yagisawa N; Arai T; Yanagisawa M
Anticancer Res; 2024 Apr; 44(4):1767-1772. PubMed ID: 38538005
[TBL] [Abstract] [Full Text] [Related]
14. Cancer-specific mortality in non-metastatic T1a renal cell carcinoma treated with radiotherapy versus partial nephrectomy.
de Angelis M; Morra S; Scheipner L; Siech C; Jannello LMI; Baudo A; Goyal JA; Tian Z; Longo N; Ahyai S; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2024 Mar; 42(1):193. PubMed ID: 38530480
[TBL] [Abstract] [Full Text] [Related]
15. Stereotactic body radiotherapy for distant metastases to the head and neck.
Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
[TBL] [Abstract] [Full Text] [Related]
16. Percutaneous Image-Guided Cryoablation of Endophytic Renal Cell Carcinoma.
Jensen CG; Dybdahl M; Valtersson J; Mussmann BR; Duus LA; Junker T; Pietersen PI; Lund L; Welch BT; Graumann O
Cardiovasc Intervent Radiol; 2024 Apr; 47(4):453-461. PubMed ID: 38483602
[TBL] [Abstract] [Full Text] [Related]
17. 25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis.
Shelton J; Zotow E; Smith L; Johnson SA; Thomson CS; Ahmad A; Murdock L; Nagarwalla D; Forman D
BMJ; 2024 Mar; 384():e076962. PubMed ID: 38479774
[TBL] [Abstract] [Full Text] [Related]
18. Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis.
Huang RS; Chow R; Chopade P; Mihalache A; Hasan A; Boldt G; Glicksman R; Simone CB; Lock M; Raman S
Radiother Oncol; 2024 May; 194():110216. PubMed ID: 38462092
[TBL] [Abstract] [Full Text] [Related]
19. The prognostic role of histomorphological subtyping in nonmetastatic papillary renal cell carcinoma after curative surgery: is subtype really irrelevant? A propensity score matching analysis of a multi-institutional real life data.
Erdem S; Bertolo R; Campi R; Capitanio U; Amparore D; Anceschi U; Mir MC; Roussel E; Pavan N; Carbonara U; Kara O; Klatte T; Marchioni M; Pecoraro A; Muselaers S; Marandino L; Diana P; Borregales L; Palumbo C; Warren H; Wu Z; Calio A; Ciccarese C; Degirmenci E; Aydin R; Rebez G; Schips L; Simone G; Minervini A; Serni S; Ozcan F
Urol Oncol; 2024 May; 42(5):163.e1-163.e13. PubMed ID: 38443238
[TBL] [Abstract] [Full Text] [Related]
20. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
[TBL] [Abstract] [Full Text] [Related]
[Next]
